Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Raw Materials (2016 - 2019)

Tandem Diabetes Care filings provide 6 years of Raw Materials readings, the most recent being $9.6 million for Q1 2019.

  • On a quarterly basis, Raw Materials fell 7.79% to $9.6 million in Q1 2019 year-over-year; TTM through Mar 2019 was $9.6 million, a 7.79% decrease, with the full-year FY2018 number at $6.6 million, down 35.88% from a year prior.
  • Raw Materials hit $9.6 million in Q1 2019 for Tandem Diabetes Care, up from $6.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $12.1 million in Q2 2016 to a low of $6.6 million in Q4 2018.
  • Median Raw Materials over the past 5 years was $10.0 million (2016), compared with a mean of $9.9 million.
  • Biggest five-year swings in Raw Materials: soared 49.7% in 2015 and later plummeted 35.88% in 2018.
  • Tandem Diabetes Care's Raw Materials stood at $10.6 million in 2015, then decreased by 11.61% to $9.4 million in 2016, then grew by 10.17% to $10.3 million in 2017, then plummeted by 35.88% to $6.6 million in 2018, then skyrocketed by 44.74% to $9.6 million in 2019.
  • The last three reported values for Raw Materials were $9.6 million (Q1 2019), $6.6 million (Q4 2018), and $8.6 million (Q3 2018) per Business Quant data.